AstraZeneca has taken a stand to be a leader in identifying a potential antibody treatment to reduce the impact and prevent the spread of COVID-19. The internal efforts of researching include a combination of clinical experts, bioprocess experts, protein engineering professionals and virology experts coming together to discover, test, develop and distribute antibody treatments that will impact the world. AstraZeneca has proven to provide a great investment opportunity for an investor, and their researching efforts surrounding the COVID-19 pandemic provides another potential opportunity.
Collaboration With Experts Brings Promising Outlooks
Not only has AstraZeneca led internal efforts on research and development, but they have also collaborated with experts in the government and academia areas. Some of the experts they have worked with come from Vanderbilt University Medical Center, the Chinese Academy of Sciences, the University of Maryland School of Medicine and the United States Army Medical Research Institute of Infectious Diseases. The collaboration has included providing genetic sequences for antibodies to aid in the efforts of undergoing preclinical efficacy and safety assessments in biosafety laboratories. While there are still no treatments approved for COVID-19, the collaboration efforts are making great strides toward minimizing the impact of the virus.
Antibody Treatments May Be Immediately Effective For Patients
While there are a lot of discussions about vaccine development, the truth is one likely will not be available until the spring of 2021 at the earliest. Vaccine development is the long-term goal to protect against COVID-19, but antibody-based treatments are going to be the immediate option for neutralizing the virus. The use of monoclonal antibodies in laboratories closely mimic the antibodies naturally formed. The goal is to protect people who have been exposed to it, and treat the virus and reduce symptoms for people who currently have it.
AstraZeneca Is Deep Into The Process Of Discovering Antibody Treatments
As an investor, knowing the timeline of a potential antibody treatment is important. The process involves finding the sources for antibodies against COVID-19, including recovered patients, testing in mice and other laboratory techniques. AstraZeneca then harnesses various technology platforms, such as hybridoma and immune replica technology to produce monoclonal antibodies and capture and screen them for assessment purposes. The overall goal is to have clinical evaluations this summer or early fall at the latest.
As AstraZeneca continues working through the process of discovering antibody treatments, they also offer an interesting investment opportunity for an investor. The important thing to note is that once the process develops far enough and receives regulatory approvals, they are equipped to develop, manufacture and distribute monoclonal antibodies.
At Stock Investing Info, we monitor the progress, development and implementation of different research areas relating to COVID-19. As pharmaceutical companies worldwide work to find effective treatments for the virus, AstraZeneca has become a clear leader and a viable option when it comes to an investment opportunity for investors. Regardless of your level of financial knowledge, our experts are here to help you understand the ins-and-outs of a fluid circumstance. Never hesitate to contact us to learn more about the opportunities available to you as an investor.